TScan Therapeutics awards Zdraveski 300,000 shares

Continued service through applicable vesting dates is required under the award's stated terms.

Rhea-AI Filing Summary

TScan Therapeutics, Inc. (TCRX) Chief Legal and Strategy Officer Zoran Zdraveski received an award reported as 300,000 shares of Voting Common Stock on October 1, 2026. His reported direct holdings following the transaction were 304,716 shares.

The award terms provide that 25% of the RSUs vest on September 30, 2028; the remaining 75% vest on the earlier of reported completion of the pivotal TSC-101 trial or September 30, 2030, subject to continued service through the applicable vesting dates and the plan and award agreement terms.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider ZDRAVESKI ZORAN

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Voting Common Stock F1	300,000	$0.00	$0.00

Holdings After Transaction: Voting Common Stock — 304,716 shares (Direct)

Footnotes (1)

1. F1. 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.

Key Figures

Awarded shares: 300,000 shares Direct holdings following transaction: 304,716 shares Initial RSU vesting: 25% +1 more

4 metrics

Awarded shares 300,000 shares Voting Common Stock award on October 1, 2026

Direct holdings following transaction 304,716 shares Reported after the October 1, 2026 transaction

Initial RSU vesting 25% Vests on September 30, 2028

Remaining RSU vesting 75% Vests on the earlier of reported completion of the pivotal TSC-101 trial or September 30, 2030, subject to continued service and award terms

Key Terms

restricted stock units, pivotal trial, Amended and Restated 2021 Equity Incentive Plan

3 terms

restricted stock units financial

"25% of the restricted stock units ("RSUs") shall vest"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

pivotal trial medical

"reporting of completion of the pivotal trial of TSC-101"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

Amended and Restated 2021 Equity Incentive Plan financial

"terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TCRX shares did Zoran Zdraveski receive?

TScan Therapeutics Chief Legal and Strategy Officer Zoran Zdraveski received an award reported as 300,000 shares of Voting Common Stock on October 1, 2026. His reported direct holdings following the transaction were 304,716 shares.

When do Zoran Zdraveski's TCRX RSUs vest?

25% of the RSUs vest on September 30, 2028; the remaining 75% vest on the earlier of reporting of completion of the pivotal trial of TSC-101 or September 30, 2030. Vesting is subject to continued service through the applicable dates and the terms of the equity incentive plan and award agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:45 PM Accepted by SEC EDGAR 10/02/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZDRAVESKI ZORAN

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	10/01/2026		A(1)		300,000	A	$0.00	304,716	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.

Remarks:

Chief Legal and Strategy Officer

	/s/ Zoran Zdraveski	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)